Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical ...

Apple debunks the hype around A.I. with a study showing that models struggle with complex reasoning, despite advanced ...

Key Takeaways Prep smarter with real-world coding challenges, system design scenarios, and behavioral questions tailored for top-tier tech roles and startups.Bo ...

We recently published a list of 10 Stocks Are Dominating Like Wall Street Titans. In this article, we are going to take a ...

After layoffs at Recursion, the company’s CEO writes about taking inspiration from an unexpected source: “The Art of Racing ...

Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.

Recursion Pharmaceuticals said on Tuesday it will lay off around 20% of its workforce and focus on developing drugs for rare diseases and cancers to reduce cash burn during a prolonged biotech ...

We recently published a list of 15 Stocks That Stole The Show Last Week. In this article, we are going to take a look at ...

Based on its latest expense profile and business plan, after cutting its staff, Recursion said it now expects its projected cash runway to extend into the fourth quarter of 2027. Recursion will pay ...